Wonder Relief offers a telemedicine‑based, AI‑assisted protocol that combines low‑dose ketamine, supplements, CBT, mindfulness, and coaching to provide a safer, non‑opioid treatment for chronic pain. The platform uses proprietary AI for real‑time safety alerts, abuse surveillance, and adaptive dosing, while licensed clinicians oversee care, enabling accelerated FDA Phase 2/3 development and scalable patient access.
Funding
$4.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with chronic pain often rely on opioid medications, which carry high risks of tolerance, dependence, overdose, and escalating healthcare costs. Access to safe, effective alternatives that can be delivered remotely is limited, leaving many individuals without adequate pain management options.
Solution
Wonder Relief offers a telemedicine‑based 12‑week protocol that combines low‑dose ketamine lozenges, organic supplements, cognitive‑behavioral therapy, mindfulness practices, and AI‑assisted coaching. Proprietary AI continuously monitors dosing, detects signs of misuse, and generates real‑time safety alerts while clinicians retain oversight through a human‑in‑the‑loop workflow. The program is designed to promote neuroplasticity and reduce opioid reliance, leveraging adaptive dosing and flow‑state techniques to enhance analgesic durability. An FDA‑aligned adaptive Phase 2/3 trial design accelerates clinical validation and regulatory clearance.
Target Audience
Primary customers are healthcare providers and pain management clinics seeking a telehealth solution for chronic pain patients who are candidates for opioid tapering, as well as insurers aiming to reduce opioid‑related costs.
Features
- Low‑dose ketamine lozenges (100–400 mg) administered 4–8 times per month as a neuromodulatory primer
- Daily organic supplement blend of functional mushrooms and botanicals to support neuroplasticity
- Integrated CBT and mindfulness‑based stress reduction modules delivered via a virtual platform
- AI‑driven personalization of dosing, timing, and intervention pathways based on patient response data
- Real‑time AI abuse surveillance and safety alerts with clinician oversight for regulatory compliance
- Continuous outcome tracking using validated scales (PHQ‑9, GAD‑7) and remote monitoring tools
- Adaptive FDA Phase 2/3 trial framework to expedite evidence generation and NDA submission